국내자료를 근거로 한 호중구감소성 발열 환자의 경험적 치료 지침

키워드

참고문헌 (217)

1. The Korean Society of Infectious Diseases, "Infectious Disease" (2007), Koonja Publishing Inc
2. Hughes WT, "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer", Clin Infect Dis, 24, pp.730~751 (2002)
3. Segal BH, "NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer- Related Infections (v.2.2009)" (2009), National Comprehensive Cancer Network
4. Bertz H, "Antimicrobial therapy of febrile complications after high-dose chemo-", radiotherapy and autologous hematopoietic stem cell transplantation-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), 2003, pp.82(2), S167~S174
5. Bohme A, "Treatment of invasive fungal infections in cancer patients-- recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 88, pp.97~110 (2009)
6. Bohme A, "Treatment of fungal infections in hematology and oncology-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 82(2), pp.S133~S140 (2003)
7. Buchheidt D, "Diagnosis and treatment of documented infections in neutropenic patients-- recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 82(2), pp.S127~S132 (2003)
8. Cornely OA, "Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 82(2), pp.S186~S200 (2003)
9. Einsele H, "Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 82(2), pp.S175~S182 (2003)
10. Fatkenheuer G, "Central venous catheter (CVC)-related infections in neutropenic patients-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 82(2), pp.S149~S157 (2003)
11. Link H, "Antimicrobial therapy of unexplained fever in neutropenic patients-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society)", Ann Hematol, 82(2), pp.S105~S117 (2003)
12. Ruhnke M, "Diagnosis of invasive fungal infections in hematology and oncology-- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 82, pp.S141~S148 (2003)
13. Sandherr M, "Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)", Ann Oncol, 17, pp.1051~1059 (2006)
14. Marchetti O, "Empirical antifungal therapy in neutropaenic cancer patients with persistent fever", Eur J Cancer Suppl, 5, pp.32~42 (2007)
15. Maertens JA, "Primary antifungal prophylaxis in leukaemia patients", Eur J Cancer Suppl, 5, pp.43~48 (2007)
16. Drgona L, "The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia", Eur J Cancer Suppl, 5, pp.13~22 (2007)
17. Cometta A, "Empirical use of anti- Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia", Eur J Cancer Suppl, 5, pp.23~31 (2007)
18. Bucaneve G, "Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients", Eur J Cancer Suppl, 5, pp.5~12 (2007)
19. Jun HX, "Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever", Int J Antimicrob Agents, 26(2), pp.S128~S140 (2005)
20. Yoshida M, "Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey", Clin Infect Dis, 39(1), pp.S11~S14 (2004)
21. Yoshida M, "Antimicrobial prophylaxis in febrile neutropenia", Clin Infect Dis, 39(1), pp.S65~S67 (2004)
22. Urabe A, "Clinical features of the neutropenic host: definitions and initial evaluation", Clin Infect Dis, 39(1), pp.S53~S55 (2004)
23. Tamura K, "Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia", Clin Infect Dis, 39(1), pp.S15~S24 (2004)
24. Tamura K, "Initial empirical antimicrobial therapy: duration and subsequent modifications", Clin Infect Dis, 39(1), pp.S59~S64 (2004)
25. Ohyashiki K, "Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients", Clin Infect Dis, 39(1), pp.S56~S58 (2004)
26. Masaoka T, "Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary", Clin Infect Dis, 39(1), pp.S49~S52 (2004)
27. Kanamaru A, "Microbiological data for patients with febrile neutropenia", Clin Infect Dis, 39(1), pp.S7~S10 (2004)
28. Anonymous, "The periodic health examination. Canadian Task Force on the Periodic Health Examination", Can Med Assoc J, 121, pp.1193~1254 (1979)
29. 최수미, "Current Antimicrobial Usage for the Management of Neutropenic Fever in Korea: A Nationwide Survey", Journal of Korean Medical Science, 23(6), pp.941~947 (2008), 대한의학회
30. Kim HS, "Comparison of rectal temperature and tympanic membrane", Nurs Sci, 10, pp.22~30 (1998)
31. Fulbrook P, "Core body temperature measurement: a comparison of axilla, tympanic membrane and pulmonary artery blood temperature", Intensive Crit Care Nurs, 13, pp.266~272 (1997)
32. Dzarr AA, "A comparison between infrared tympanic thermometry, oral and axilla with rectal thermometry in neutropenic adults", Eur J Oncol Nurs, 13, pp.250~254 (2009)
33. Ciuraru NB, "The influence of mucositis on oral thermometry: when fever may not reflect infection", Clin Infect Dis, 46, pp.1859~1863 (2008)
34. Bodey GP, "Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia", Ann Intern Med, 64, pp.328~340 (1966)
35. Bodey GP, "Narboni. Fever and infection in leukemic patients: a study of 494 consecutive patients", Cancer, 41, pp.1610~1622 (1978)
36. Sickles EA, "Clinical presentation of infection in granulocytopenic patients", Arch Intern Med, 135, pp.715~719 (1975)
37. Heussel CP, "Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography", J Clin Oncol, 17, pp.796~805 (1999)
38. Klastersky J, "The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients", J Clin Oncol, 18, pp.3038~3051 (2000)
39. Talcott JA, "The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation", Arch Intern Med, 148, pp.2561~2568 (1988)
40. Talcott JA, "Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule", J Clin Oncol, 10, pp.316~322 (1992)
41. Talcott JA, "Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule", J Clin Oncol, 12, pp.107~114 (1994)
42. Jung JS, "Risk prediction factors in febrile neutropenic patients", J Korean Soc Emerg Med, 11, pp.305~315 (2000)
43. Shin Wan Shik, "Prognostic Factors Influencing Infection-related Mortality in Patients with Acute Leukemia in Korea", Journal of Korean Medical Science, 20(1), pp.31~35 (2005), 대한의학회
44. Gafter-Gvili A, "Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients", Ann Intern Med, 142, pp.979~995 (2005)
45. Engels EA, "Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis", J Clin Oncol, 16, pp.1179~1187 (1998)
46. Ito JI, "Antibacterial prophylaxis in patients with cancer and neutropenia", N Engl J Med, 354, pp.90~94 (2006)
47. Cullen M, "Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas", N Engl J Med, 353, pp.988~998 (2005)
48. Bucaneve G, "Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia", N Engl J Med, 353, pp.977~987 (2005)
49. Lee DG, "Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial", Korean J Intern Med, 17, pp.38~44 (2002)
50. Thomas X, "Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study", Presse Med, 29, pp.1745~1751 (2000)
51. Talbot GH, "Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group", Antimicrob Agents Chemother, 37, pp.474~482 (1993)
52. Lew MA, "Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation", Transplantation, 51, pp.630~636 (1991)
53. Karp JE, "Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial", Ann Intern Med, 106, pp.1~7 (1987)
54. Robenshtok E, "Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stemcell transplantation: systematic review and meta-analysis", J Clin Oncol, 25, pp.5471~5489 (2007)
55. Goodman JL, "A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation", N Engl J Med, 326, pp.845~851 (1992)
56. Slavin MA, "Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-- a prospective, randomized, double-blind study", J Infect Dis, 171, pp.1545~1552 (1995)
57. Rotstein C, "Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group", Clin Infect Dis, 28, pp.331~340 (1999)
58. Winston DJ, "Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial", Ann Intern Med, 118, pp.495~503 (1993)
59. Schaffner A, "Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias", J Infect Dis, 172, pp.1035~1041 (1995)
60. Young GA, "A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group", Eur J Cancer, 35, pp.1208~1213 (1999)
61. Philpott-Howard JN, "Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group", J Antimicrob Chemother, 31, pp.973~984 (1993)
62. Menichetti F, "Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B", Ann Intern Med, 120, pp.913~918 (1994)
63. Annaloro C, "Efficacy of different prophylactic antifungal regimens in bone marrow transplantation", Haematologica, 80, pp.512~517 (1995)
64. Huijgens PC, "Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology", J Clin Pathol, 52, pp.376~380 (1999)
65. Glasmacher A, "An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia", J Antimicrob Chemother, 57, pp.317~325 (2006)
66. Marr KA, "Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants", Blood, 103, pp.1527~1533 (2004)
67. Morgenstern GR, "A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group", Br J Haematol, 105, pp.901~911 (1999)
68. Oren I, "A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients", Bone Marrow Transplant, 38, pp.127~134 (2006)
69. Winston DJ, "Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial", Ann Intern Med, 138, pp.705~713 (2003)
70. Slordal L, "Heart failure induced by non-cardiac drugs", Drug Saf, 29, pp.567~586 (2006)
71. Nagappan V, "Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent", Clin Infect Dis, 45, pp.1610~1617 (2007)
72. "Schering-Plough announces FDA approval of NOXAFIL(R) (posaconazole) for treatment of oropharyngeal candidiasis (OPC)"[URL]
73. Cornely OA, "Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia", N Engl J Med, 356, pp.348~359 (2007)
74. van Burik JA, "Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation", Clin Infect Dis, 39, pp.1407~1416 (2004)
75. Hiramatsu Y, "Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation", Int J Hematol, 88, pp.588~595 (2008)
76. Wolff SN, "Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group", Bone Marrow Transplant, 25, pp.853~859 (2000)
77. Bodey GP, "Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B", Cancer, 73, pp.2099~2106 (1994)
78. Tollemar J, "Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients", Bone Marrow Transplant, 12, pp.577~582 (1993)
79. Kelsey SM, "Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebocontrolled study", Bone Marrow Transplant, 23, pp.163~168 (1999)
80. Tollemar J, "Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies", Transplant Proc, 26, pp.1833~ (1994)
81. Penack O, "Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial", Ann Oncol, 17, pp.1306~1312 (2006)
82. Schwartz S, "Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial", Blood, 93, pp.3654~3661 (1999)
83. Alexander BD, "Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation", Transpl Infect Dis, 8, pp.13~20 (2006)
84. Rijnders BJ, "Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial", Clin Infect Dis, 46, pp.1401~1408 (2008)
85. 최수미, "조혈모세포이식 환자에서 침습성 진균 감염에 대한이트라코나졸 액과 플루코나졸 시럽의 예방 효과 :전향적, 무작위, 비교 임상시험", Infection and Chemotherapy, 37(2), pp.71~78 (2005), 대한감염학회
86. Menichetti F, "Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo- controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto", Clin Infect Dis, 28, pp.250~255 (1999)
87. Nucci M, "A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients", Clin Infect Dis, 30, pp.300~305 (2000)
88. Akiyama H, "Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies", Mycoses, 36, pp.373~378 (1993)
89. Riley DK, "The prophylactic use of low-dose amphotericin B in bone marrow transplant patients", Am J Med, 97, pp.509~514 (1994)
90. Kaptan K, "Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia", J Infect Chemother, 9, pp.40~45 (2003)
91. Kern W, "Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study", German AML Cooperative Group. Cancer, 83, pp.291~301 (1998)
92. Lass-Florl C, "Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution", Ann Hematol, 82, pp.565~569 (2003)
93. Van Delden C, "Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary", Clin Microbiol Infect, 1, pp.24~30 (1995)
94. Ullmann AJ, "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease", N Engl J Med, 356, pp.335~347 (2007)
95. Hughes WT, "Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis", N Engl J Med, 316, pp.1627~1632 (1987)
96. Green H, "Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIVinfected patients: systematic review and meta-analysis of randomized controlled trials", Mayo Clin Proc, 82, pp.1052~1059 (2007)
97. Green H, "Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients", Cochrane Database Syst Rev, pp.CD005590~ (2007)
98. Wadhwa PD, "Infectious complications of chronic lymphocytic leukemia", Semin Oncol, 33, pp.240~249 (2006)
99. Martin SI, "Infectious complications associated with alemtuzumab use for lymphoproliferative disorders", Clin Infect Dis, 43, pp.16~24 (2006)
100. Sudhoff T, "Prophylactic strategies to meet infectious complications in fludarabine-treated CLL", Leukemia, 11(2), pp.S38~S41 (1997)
101. El-Sadr WM, "A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)", Clin Infect Dis, 29, pp.775~783 (1999)
102. Vasconcelles MJ, "Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections", Biol Blood Marrow Transplant, 6, pp.35~43 (2000)
103. Souza JP, "High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis", Clin Infect Dis, 29, pp.1467~1471 (1999)
104. Meyers JD, "Infection with herpes simplex virus and cell-mediated immunity after marrow transplant", J Infect Dis, 142, pp.338~346 (1980)
105. Schubert MM, "Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow transplantation: analysis of factors associated with infection", Oral Surg Oral Med Oral Pathol, 70, pp.286~293 (1990)
106. Barton T, "Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer", Clin Infect Dis, 32, pp.391~395 (2001)
107. Herrmann RP, "Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma", Bone Marrow Transplant, 24, pp.1213~1217 (1999)
108. Seropian S, "Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option", Bone Marrow Transplant, 23, pp.599~605 (1999)
109. Lee JT, "Prevalence of antibody to herpes simplex virus", Korean J Dermatol, 31, pp.38~46 (1993)
110. Glenny AM, "Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer", Cochrane Database Syst Rev, pp.CD006706~ (2009)
111. Yahav D, "Antiviral prophylaxis in haematological patients: systematic review and meta-analysis", Eur J Cancer, 45, pp.3131~3148 (2009)
112. Liesveld JL, "Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients", Biol Blood Marrow Transplant, 8, pp.662~665 (2002)
113. Warkentin DI, "Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients", Ann Pharmacother, 36, pp.1525~1531 (2002)
114. Wade JC, "Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation", Ann Intern Med, 100, pp.823~828 (1984)
115. Tomblyn M, "Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective", Preface. Bone Marrow Transplant, 44, pp.453~455 (2009)
116. 최수미, "급성 백혈병 환자의 감염양상 : 관해 유도 및 재관해유도 화학요법 환자군의 비교", Infection and Chemotherapy, 35(2), pp.78~85 (2003), 대한감염학회
117. Kim HB, "Infections in patients with acute leukemia (1993-1996)", Korean J Hematol, 34, pp.359~365 (1999)
118. Sun Hee Park, "Current Trends of Infectious Complications following Hematopoietic Stem Cell Transplantation in a Single Center", Journal of Korean Medical Science, 21(2), pp.199~207 (2006), 대한의학회
119. 노영희, "백혈병 환자에서 호중구 감소성 발열의 양상과 예후 인자에 관한 연구 - 1996~2001년", Infection and Chemotherapy, 34(3), pp.152~159 (2002), 대한감염학회
120. 이지영, "동종 조혈 모세포 이식 환자에서 감염증의 양상에 대한 고찰", 대한내과학회지, 72(2), pp.200~208 (2007), 대한내과학회
121. Kim JS, "The patterns of infection and therapy in cancer patients receiving chemotherapy", J Kor Soc Health- Syst Pharm, 17, pp.481~500 (2000)
122. Freifeld A, "A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy", N Engl J Med, 341, pp.305~311 (1999)
123. Hidalgo M, "Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial", Cancer, 85, pp.213~219 (1999)
124. Kern WV, "Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer", N Engl J Med, 341, pp.312~318 (1999)
125. Malik IA, "Feasibility of outpatient management of fever in cancer patients with lowrisk neutropenia: results of a prospective randomized trial", Am J Med, 98, pp.224~231 (1995)
126. Rolston KV, "Early empiric antibiotic therapy for febrile neutropenia patients at low risk", Infect Dis Clin North Am, 10, pp.223~237 (1996)
127. Rolston KV, "Oral moxifloxacin for outpatient treatment of lowrisk, febrile neutropenic patients", Support Care Cancer (2009)
128. Aquino VM, "Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer", Cancer, 88, pp.1710~1714 (2000)
129. Giamarellou H, "Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever", Antimicrob Agents Chemother, 44, pp.3264~3271 (2000)
130. Kerr KG, "Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy", Support Care Cancer, 7, pp.28~30 (1999)
131. De Pauw BE, "Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group", Ann Intern Med, 120, pp.834~844 (1994)
132. Cometta A, "Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program", Antimicrob Agents Chemother, 40, pp.1108~1115 (1996)
133. Rubinstein E, "Ceftazidime monotherapy vs. ceftriaxone", tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group, 1995, pp.20, 1217~1228
134. Winston DJ, "Betalactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone", Ann Intern Med, 115, pp.849~859 (1991)
135. Pizzo PA, "A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia", N Engl J Med, 315, pp.552~558 (1986)
136. Behre G, "Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients", Ann Hematol, 76, pp.73~80 (1998)
137. Bohme A, "Piperacillin", tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study, 1998, pp.3, 324~330
138. Del Favero A, "A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia", Clin Infect Dis, 33, pp.1295~1301 (2001)
139. Akova M, "Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey", Int J Antimicrob Agents, 13, pp.15~19 (1999)
140. Yamamura D, "Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients", Antimicrob Agents Chemother, 41, pp.1704~1708 (1997)
141. Freifeld AG, "Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem", J Clin Oncol, 13, pp.165~176 (1995)
142. Bow EJ, "A randomized, openlabel, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies", Clin Infect Dis, 43, pp.447~459 (2006)
143. Johnson MP, "Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy", J Infect Dis, 162, pp.981~983 (1990)
144. Feld R, "Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial", J Clin Oncol, 18, pp.3690~3698 (2000)
145. Vandercam B, "Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients", Ann Hematol, 79, pp.152~157 (2000)
146. Pazdur R, "Cancer management: a multidisciplinary approach" (2009), CMP Medica
147. Yahav D, "Efficacy and safety of cefepime: a systematic review and meta-analysis", Lancet Infect Dis, 7, pp.338~348 (2007)
148. Paul M, "Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials", J Antimicrob Chemother, 57, pp.176~189 (2006)
149. 정현욱, "발열을 동반한 호중구감소증에서 Cefepime 단독투여와 Ceftazidime 및 Tobramycin 병합투여의 효능비교", Infection and Chemotherapy, 36(6), pp.341~349 (2004), 대한감염학회
150. Lee DH, "A comparative study of cefepime versus ceftazidime monotherapy as empirical therapy for febrile episodes in neutropenic patients", J Korean Soc chem, 20, pp.243~251 (2002)
151. Flaherty JP, "Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients", Am J Med, 87, pp.278S~282S (1989)
152. Cometta A, "Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer", Antimicrob Agents Chemother, 39, pp.445~452 (1995)
153. Cordonnier C, "Cefepime", amikacin versus ceftazidime, Clin Infect Dis, pp.1997, 24[DOI]
154. Peacock JE, "Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial", Ann Intern Med, 137, pp.77~87 (2002)
155. Sanz MA, "Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial", J Antimicrob Chemother, 50, pp.79~88 (2002)
156. Rybak MJ, "Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity", Antimicrob Agents Chemother, 43, pp.1549~1555 (1999)
157. Torfoss D, "Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial", J Antimicrob Chemother, 59, pp.711~717 (2007)
158. 최수미, "호중구 감소성 발열 환자에서 패혈성 쇽의 임상양상과 위험인자", Infection and Chemotherapy, 35(6), pp.370~376 (2003), 대한감염학회
159. Elting LS, "Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care", J Clin Oncol, 18, pp.3699~3706 (2000)
160. Kim WS, "The efficacy and safety of oral ciprofloxacin therapy for low-risk febrite patients with neutropenia during cancer chemotherapy", J Korean Soc Chem, 18, pp.29~38 (2000)
161. Anonymous, "Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada- Clinical Trials Group", J Infect Dis, 163, pp.951~958 (1991)
162. Micozzi A, "Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients", Br J Haematol, 76(2), pp.19~23 (1990)
163. Vardakas KZ, "Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a metaanalysis of randomised controlled trials", Lancet Infect Dis, 5, pp.431~439 (2005)
164. Paul M, "Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials", J Antimicrob Chemother, 55, pp.436~444 (2005)
165. Elting LS, "Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials", Clin Infect Dis, 25, pp.247~259 (1997)
166. Glasmacher A, "An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients", Clin Microbiol Infect, 11(5), pp.17~23 (2005)
167. Kim SH, "Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia", J Antimicrob Chemother, 54, pp.489~497 (2004)
168. Young Uh, "Antimicrobial Susceptibility Patterns and Macrolide Resistance Genesof beta-Hemolytic Viridans Group Streptococci in a Tertiary KoreanHospital", Journal of Korean Medical Science, 22(5), pp.791~794 (2007), 대한의학회
169. Uh Y, "Antimicrobial susceptibilities of viridans streptococci isolated from blood cultures during recent period", J Lab Med Qual Assur, 24, pp.225~230 (2002)
170. Cometta A, "Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy", Clin Infect Dis, 37, pp.382~389 (2003)
171. Erjavec Z, "A prospective, randomized, double-blinded, placebocontrolled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy", J Antimicrob Chemother, 45, pp.843~849 (2000)
172. Svetitsky S, "Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis", Antimicrob Agents Chemother, 53, pp.4069~4079 (2009)
173. Soriano A, "Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia", Clin Infect Dis, 46, pp.193~200 (2008)
174. Brink AJ, "Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis", Int J Antimicrob Agents, 32, pp.455~458 (2008)
175. Press OW, "Hickman catheter infections in patients with malignancies", Medicine, 63, pp.189~200 (1984)
176. Cercenado E, "A conservative procedure for the diagnosis of catheterrelated infections", Arch Intern Med, 150, pp.1417~1420 (1990)
177. Blot F, "Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral- blood cultures", Lancet, 354, pp.1071~1077 (1999)
178. Raad I, "Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections", Ann Intern Med, 140, pp.18~25 (2004)
179. Krause R, "Detection of catheter-related bloodstream infections by the differentialtime- to-positivity method and gram stain-acridine orange leukocyte cytospin test in neutropenic patients after hematopoietic stem cell transplantation", J Clin Microbiol, 42, pp.4835~4837 (2004)
180. Abdelkefi A, "Difference in time to positivity is useful for the diagnosis of catheter-related bloodstream infection in hematopoietic stem cell transplant recipients", Bone Marrow Transplant, 35, pp.397~401 (2005)
181. Blot F, "Earlier positivity of central-venousversus peripheral-blood cultures is highly predictive of catheter-related sepsis", J Clin Microbiol, 36, pp.105~109 (1998)
182. Mermel LA, "Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.1~45 (2009)
183. Wilcox MH, "Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study", Clin Infect Dis, 48, pp.203~212 (2009)
184. Kim SH, "Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia", Infect Control Hosp Epidemiol, 24, pp.897~904 (2003)
185. Dugdale DC, "Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters", Am J Med, 89, pp.137~141 (1990)
186. Pizzo PA, "Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia", Am J Med, 72, pp.101~111 (1982)
187. Anonymous, "Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989;86:668-72. 188. Klastersky J. Empirical antifungal therapy", Int J Antimicrob Agents, 23, pp.105~112 (2004)
188. Wingard JR, "Empirical antifungal therapy in treating febrile neutropenic patients", Clin Infect Dis, 39(1), pp.S38~S43 (2004)
189. Goldberg E, "Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis", Eur J Cancer, 44, pp.2192~2203 (2008)
190. Nivoix Y, "Factors associated with overall and attributable mortality in invasive aspergillosis", Clin Infect Dis, 47, pp.1176~1184 (2008)
191. 유진홍, "혈액질환 환자에서 조혈모세포 이식과화학요법 후의 침습성 진균감염의 분석", Infection and Chemotherapy, 36(1), pp.40~45 (2004), 대한감염학회
192. Walsh TJ, "Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America", Clin Infect Dis, 46, pp.327~360 (2008)
193. Pappas PG, "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America", Clin Infect Dis, 48, pp.503~535 (2009)
194. Michallet M, "Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation", J Clin Oncol, 27, pp.3398~3409 (2009)
195. 이진솔, "Species Distribution and Susceptibility to Azole Antifungals of Candida Bloodstream Isolates from Eight University Hospitals in Korea", Yonsei Medical Journal, 48(5), pp.779~786 (2007), 연세대학교의과대학
196. Bal AM, "Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia", Int J Antimicrob Agents, 29, pp.501~509 (2007)
197. Walsh TJ, "Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group", N Engl J Med, 340, pp.764~771 (1999)
198. Walsh TJ, "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", N Engl J Med, 346, pp.225~234 (2002)
199. Walsh TJ, "Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia", N Engl J Med, 351, pp.1391~1402 (2004)
200. Girmenia C, "Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO)", Clin Infect Dis, 49, pp.1226~1236 (2009)
201. Prentice HG, "A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients", Br J Haematol, 98, pp.711~718 (1997)
202. Boogaerts M, "Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial", Ann Intern Med, 135, pp.412~422 (2001)
203. Sun Hee Park, "Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever", The Korean Journal of Internal Medicine, 21(3), pp.165~172 (2006), 대한내과학회
204. Schuler U, "Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy", Onkologie, 30, pp.185~191 (2007)
205. Segal BH, "Aspergillosis", N Engl J Med, 360, pp.1870~1884 (2009)
206. Winston DJ, "A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer", Am J Med, 108, pp.282~289 (2000)
207. De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46[DOI]
208. Ben-Ami R, "Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges", Curr Opin Infect Dis, 22, pp.376~384 (2009)
209. Maertens J, "Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study", Clin Infect Dis, 41, pp.1242~1250 (2005)
210. Cordonnier C, "Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial", Clin Infect Dis, 48, pp.1042~1051 (2009)
211. Yoo JH, "Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases", Clin Infect Dis, 40, pp.392~398 (2005)
212. Mennink-Kersten MA, "Non-culture-based diagnostics for opportunistic fungi", Infect Dis Clin North Am, 20, pp.711~727 (2006)
213. 송경호, "침습성 아스페르길루스증 진단을 위한 갈락토만난 항원 검사의 유용성 평가", Infection and Chemotherapy, 41(2), pp.82~89 (2009), 대한감염학회
214. O'Shaughnessy EM, "Laboratory diagnosis of invasive mycoses", Infect Dis Clin North Am, 17, pp.135~158 (2003)
215. Pfeiffer CD, "Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis", Clin Infect Dis, 42, pp.1417~1427 (2006)
216. Hachem RY, "Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients", J Clin Microbiol, 47, pp.129~133 (2009)
217. Jin-Hong Yoo, "Comparison of the Real-time Nucleic Acid Sequence-basedAmplification (RTi-NASBA) with Conventional NASBA, andGalactomannan Assay for the Diagnosis of Invasive Aspergillosis", Journal of Korean Medical Science, 22(4), pp.672~676 (2007), 대한의학회

관련 논문AI추천